Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Orange County Ophthalmology
Garden Grove, California, United States
Harvard Eye Associates
Laguna Hills, California, United States
Cincinnati Eye Institute
Edgewood, Kentucky, United States
Central Corneal Thickness (CCT)
Mean change from baseline in CCT by ultrasound pachymetry
Time frame: Baseline & 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Advance Eye Associates
South Dartmouth, Massachusetts, United States
Chu Vision Institute
Bloomington, Minnesota, United States
Minnesota Eye Care
Minnetonka, Minnesota, United States
Ophthalmology Associates
St Louis, Missouri, United States
Vance Thompson Vision
West Fargo, North Dakota, United States
Comprehensive Eye Care
Westerville, Ohio, United States
Vance Thompson Vision
Sioux Falls, South Dakota, United States
...and 2 more locations